

Inflammatory Bowel Disease Market Worth \$26.3 Billion by 2027 At A Growth Rate of 5.9% - IndustryARC

Increasing Cases Of Inflammatory Bowel Disease Fuel the Growth Of The Inflammatory Bowel Disease Market.

HYDERABAD, TELANGANA, INDIA, September 29, 2022 / EINPresswire.com/ -- IndustryARC, in its latest report, predicts that The Inflammatory Bowel Disease Market Size is estimated to reach \$26.3 billion by 2027 and is poised to grow at a CAGR of 5.9% over the forecast period of 2022-2027. According to a Medscape article published in 2020, the highest



rate of IBD is assumed to be in developed countries. The incidence of IBD is between 0.5-24.5 cases per 100,000 person-years for Crohns disease and 0.1-16 cases per 100,000 person-years for ulcerative colitis globally. The report offers a complete analysis of the market, its major segments, growth factors, trends, drivers and challengers, key players and more.

Click here to browse the complete report summary: https://www.industryarc.com/Report/15917/inflammatory-bowel-disease-market.html

Key takeaways:

- 1. Geographically, North America held a dominant market share in the year 2021, owing to the increasing prevalence of Inflammatory Bowel Diseases, and developed healthcare facilities assist the growth of the Inflammatory Bowel Disease Market Size in this region.
- 2. The rising consciousness among consumers propels the growth of the Inflammatory Bowel Disease Market Size in this region.
- 3. The Inflammatory Bowel Disease Market is predicted to grow owing to the growing burden of Inflammatory Bowel Disease around the world and raising consciousness among consumers.

However, the high price of treatment may limit market growth over the forecast period 2022-2027.

4. A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Inflammatory Bowel Disease Market Report.

Interested in knowing more relevant information? Click here: https://www.industryarc.com/pdfdownload.php?id=15917

Segmental Analysis:

- 1. The Inflammatory Bowel Disease Market based on type can be further segmented into Ulcerative Colitis and Crohns Disease. The Crohn's segment held a dominant market share in the year 2021. This is owing to the increasing prevalence of Crohns disease and growing number of patients undergoing treatment for Crohns disease around the world.
- 2. Inflammatory Bowel Disease Market based on the route of administration can be further segmented into Oral, and Injectables. The injectables segment held a dominant market share in the year 2021. This is the result of the increasing use of biologics for the treatment of ulcerative colitis and Crohns disease.
- 3. The Inflammatory Bowel Disease Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 38% in the year 2021. This is the result of the increasing number of cases of inflammatory bowel disease in this region.

Competitive Landscape:

The top 5 players in the Inflammatory Bowel Disease Industry are -

- 1. ABBOTT LABORATORIES
- 2. Amgen Inc.
- 3. ASTRAZENECA PLC
- 4. ELI-LILLY
- 5. INDEX PHARMACEUTICALS HOLDINGS AB

Click on the following link to buy the Inflammatory Bowel Disease Market Report: https://www.industryarc.com/reports/request-quote?id=15917

Why Choose IndustryARC?

IndustryARC is one of the leading market research and consulting firms in the world. It produces over 500 unique market reports annually. If you are looking for a detailed overview of a particular market, you can simply connect with the team at IndustryARC. You can not only buy your preferred market report from the website, but also get personalized assistance on specific reports.

Related Reports:

A. Rhino Conjunctivitis Market https://www.industryarc.com/Report/16230/rhinoconjunctivitis-market.html

B. Monoclonal Antibodies Market https://www.industryarc.com/Report/16114/monoclonal-antibodies-market.html

Venkat Reddy
IndustryARC
+1 614-588-8538
venkat@industryarc.com
Visit us on social media:
Facebook
Twitter

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/593381075

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 Newsmatics Inc. All Right Reserved.